BioAlliance Pharma SA announces the grant of its main patent on the Lauriad(R) technology in Europe

BioAlliance Pharma SA announces the grant of its main patent on the Lauriad® technology in Europe

PARIS–(EMWNews – August 22, 2008) – BioAlliance Pharma announces the grant of

its main patent on the Lauriad® technology in Europe

The patent has been validated in the main European countries and

the opposition period has now expired.

Paris, August 22, 2008 – BioAlliance Pharma SA (Euronext Paris:

FR0010095596-BIO),

the specialty pharmaceutical company focused on the treatment of

opportunistic infections in cancer

and HIV, today announced the grant of its main patent on the

Lauriad® technology in Europe.

The patent describes and protects a muco-adhesive tablet for

various applications in the field of opportunistic infections

associated with AIDS and cancer. It has been validated in the main

European countries and the opposition period has now expired.

“The grant of this patent acknowledges the true innovation behind

the Lauriad® muco-adhesive technology”, stated Dominique

Costantini, President and CEO of BioAlliance Pharma. “It

reinforces our positioning in the target markets for the

Lauriad® technology: oropharyngeal candidiasis, labial herpes

and chronic pain”.

Given BioAlliance Pharma’s commitment to the development and

commercialization of innovative products, intellectual property

(IP) is at the heart of the company’s business activity. The

company is developing a pro-active IP strategy that is tightly

coupled to its R&D projects.

BioAlliance Pharma’s patent portfolio now encompasses 25 published

patent families (comprising 196 patent applications and granted

patents) covering innovative technologies or products in the

fields of opportunistic infections, cancer and AIDS. More than

half the portfolio is made up of granted patents.

About BioAlliance Pharma

BioAlliance Pharma SA is a specialty pharmaceutical company

focused on the treatment of opportunistic infections in cancer and

HIV. The company develops and commercializes innovative products

which address drug resistance issues. BioAlliance Pharma has

launched its first portfolio product (Loramyc®) in France and,

more recently, in the UK, Germany and Denmark, and has already

received European Marketing Authorizations in Belgium and

Luxemburg. The product has also completed a pivotal Phase III

clinical trial in the United States in oropharyngeal candidiasis.

The company is also performing a Phase III trial in labial herpes

with acyclovir Lauriad® (which is based on the same Lauriad®

muco-adhesive technology as Loramyc®, enabling targeted release

at the disease site). BioAlliance Pharma also has a second

technology (the Transdrug® nanoparticle technology, designed

specifically for intracellular targeting) and, furthermore, is

developing a new therapeutic entities program in oncology and

infectious disease. BioAlliance Pharma has established several

strategic alliances for commercializing Loramyc®, with

agreements in 2007 for Europe (with the SpeBio joint venture) and

the United States (with Par Pharmaceutical) and in 2008 for Asia

(Korea, Malaysia, Singapore and Taiwan with Handok Pharmaceuticals

and then China with Novamed). In May and August 2008, the company

expanded its product portfolio by acquiring the Europe commercial

rights to, respectively, ondansetron Oral Spray (OS) from NovaDel

Pharma Inc. (Amex: NVD) and ondansetron RapidFilmTM from

APR/Labtec. For more information, visit BioAlliance Pharma’s

website at www.bioalliancepharma.com.

Disclaimer

This communication expressly or implicitly contains certain

forward-looking statements concerning BioAlliance Pharma SA and

its business. Such statements involve certain known and unknown

risks, uncertainties and other factors, which could cause the

actual results, financial condition, performance or achievements

of BioAlliance Pharma SA to be materially different from any

future results, performance or achievements expressed or implied

by such forward-looking statements. BioAlliance Pharma SA is

providing this communication as of this date and does not

undertake to update any forward-looking statements contained

herein as a result of new information, future events or otherwise.

For a discussion of risks and uncertainties which could cause

actual results, financial condition, performance or achievements

of BioAlliance Pharma SA to differ from those contained in the

forward-looking statements, please refer to the Risk Factors

(“Facteurs de Risque”) section of the reference document approved

by the AMF on April 11 2008 under the number R. 08-021, which is

available on the AMF website (http://www.amf-france.org) or on

BioAlliance Pharma S.A.’s website

(http://www.bioalliancepharma.com).

This information is provided by HUGIN